344079 Flurbiprofen - CAS 5104-49-4 - Calbiochem

344079
View Pricing & Availability

Overview

Replacement Information

Key Specifications Table

Empirical FormulaCAS #
C₁₅H₁₃FO₂ 5104-49-4

Pricing & Availability

Catalog Number AvailabilityPackaging Qty/Pack Price Quantity
344079-100MG
Retrieving availability...
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      Alu drum 100 mg
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity needs to be mulitiple of
      Upon Order Completion More Information
      You Saved ()
       
      Request Pricing
      Description
      OverviewA mixture of S(+) and R(–) enantiomers. A cell-permeable, non-steroidal anti-inflammatory agent that acts as a potent inhibitor of cyclooxygenase (IC50 = 5 nM for LPS-induced COX in human peripheral blood cells). Strongly inhibits insoluble transthyretin (TTR) amyloid fibril formation. Suppresses iNOS expression in RAW 264.7 macrophages. Reduces microglial activation and β-amyloid deposit in APP+PS1 transgenic mice.
      Catalogue Number344079
      Brand Family Calbiochem®
      Synonyms(±)-2-Fluoro-α-methyl[1,1ʹ-biphenyl]-4-acetic Acid, U-27182
      References
      ReferencesJantzen, P.T., et al. 2002. J. Neurosci. 22, 2246.
      Hinz, R., et al. 2001. Pharmacol. Res. 18, 151.
      Klabunde, T., et al. 2000. Nat. Struct. Biol. 7, 312.
      Range, S.P., et al. 2000. Eur. Respir. J. 15, 751.
      van Haeringen, N.J., et al. 2000. J. Ocul. Pharmacol. Ther. 16, 353.
      Curnock, A.P., et al. 1997. J. Pharmacol. Exp. Ther. 282, 339.
      Reindeau, D., et al. 1997. Can. J. Physiol. Pharmacol. 75, 1088.
      Wechter, W.J., et al. 1997. Cancer Res. 57, 4316.
      Karmali, R.A., and Marsh, J. 1986. Prostaglandins Leukot. Med. 23, 11.
      Karmali, R.A., and Marsh, J. 1985. Prostaglandins Leukot. Med. 20, 283.
      Product Information
      CAS number5104-49-4
      ATP CompetitiveN
      FormWhite solid
      Hill FormulaC₁₅H₁₃FO₂
      Chemical formulaC₁₅H₁₃FO₂
      ReversibleN
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetCyclooxygenase
      Primary Target IC<sub>50</sub>5 nM for LPS-induced COX
      Purity≥98% by HPLC
      Physicochemical Information
      Cell permeableY
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      RTECSDU8341000
      Safety Information
      R PhraseR: 25

      Toxic if swallowed.
      S PhraseS: 36/37/39-45

      Wear suitable protective clothing, gloves and eye/face protection.
      In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible).
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Toxic & Carcinogenic / Teratogenic
      Hazardous Materials Attention: Due to the nature of the Hazardous Materials in this shipment, additional shipping charges may be applied to your order. Certain sizes may be exempt from the additional hazardous materials shipping charges. Please contact your local sales office for more information regarding these charges.
      Storage +15°C to +30°C
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze at -20°C. Stock solutions are stable for up to 6 months at 4°C. Further dilution of stock solution in aqueous medium should be made just prior to use.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications

      Documentation

      Flurbiprofen - CAS 5104-49-4 - Calbiochem SDS

      Title

      Safety Data Sheet (SDS) 

      Flurbiprofen - CAS 5104-49-4 - Calbiochem Certificates of Analysis

      TitleLot Number
      344079

      References

      Reference overview
      Jantzen, P.T., et al. 2002. J. Neurosci. 22, 2246.
      Hinz, R., et al. 2001. Pharmacol. Res. 18, 151.
      Klabunde, T., et al. 2000. Nat. Struct. Biol. 7, 312.
      Range, S.P., et al. 2000. Eur. Respir. J. 15, 751.
      van Haeringen, N.J., et al. 2000. J. Ocul. Pharmacol. Ther. 16, 353.
      Curnock, A.P., et al. 1997. J. Pharmacol. Exp. Ther. 282, 339.
      Reindeau, D., et al. 1997. Can. J. Physiol. Pharmacol. 75, 1088.
      Wechter, W.J., et al. 1997. Cancer Res. 57, 4316.
      Karmali, R.A., and Marsh, J. 1986. Prostaglandins Leukot. Med. 23, 11.
      Karmali, R.A., and Marsh, J. 1985. Prostaglandins Leukot. Med. 20, 283.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision17-October-2017 JSW
      Synonyms(±)-2-Fluoro-α-methyl[1,1ʹ-biphenyl]-4-acetic Acid, U-27182
      DescriptionA mixture of S(+) and R(-) enantiomers. A cell-permeable, non-steroidal anti-inflammatory (NSAID) agent that acts as a potent inhibitor of cyclooxygenase (IC50 = 5 nM for LPS-induced COX in human peripheral blood cells). The S(+) enantiomer is reported to be more potent as a COX-2 inhibitor than the R(-) enantiomer. Suppresses iNOS expression in RAW 264.7 macrophages. Reduces Aβ loads and Congo Red staining in APP+PS1 transgenic mice
      FormWhite solid
      CAS number5104-49-4
      RTECSDU8341000
      Chemical formulaC₁₅H₁₃FO₂
      Structure formulaStructure formula
      Purity≥98% by HPLC
      SolubilityDMSO (50 mg/ml)
      Storage +15°C to +30°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze at -20°C. Stock solutions are stable for up to 6 months at 4°C. Further dilution of stock solution in aqueous medium should be made just prior to use.
      Toxicity Toxic & Carcinogenic / Teratogenic
      Merck USA index14, 4199
      ReferencesJantzen, P.T., et al. 2002. J. Neurosci. 22, 2246.
      Hinz, R., et al. 2001. Pharmacol. Res. 18, 151.
      Klabunde, T., et al. 2000. Nat. Struct. Biol. 7, 312.
      Range, S.P., et al. 2000. Eur. Respir. J. 15, 751.
      van Haeringen, N.J., et al. 2000. J. Ocul. Pharmacol. Ther. 16, 353.
      Curnock, A.P., et al. 1997. J. Pharmacol. Exp. Ther. 282, 339.
      Reindeau, D., et al. 1997. Can. J. Physiol. Pharmacol. 75, 1088.
      Wechter, W.J., et al. 1997. Cancer Res. 57, 4316.
      Karmali, R.A., and Marsh, J. 1986. Prostaglandins Leukot. Med. 23, 11.
      Karmali, R.A., and Marsh, J. 1985. Prostaglandins Leukot. Med. 20, 283.